FMR1 and fragile X syndrome: As is the case for many drugs acting on the central nervous system, there may be subpopulations of individuals with FXS that are drug responders, as predicted by FMR1 mutation type, FMRP levels, electrophysiological parameters, or other biomarker responses, given that these parameters can predict clinical phenotype (42).